PUBLISHER: DataM Intelligence | PRODUCT CODE: 1374820
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1374820
Alcoholic hepatitis is an inflammatory liver disorder that is induced by regular increased alcohol consumption. Processing extensive quantities of alcohol can impair liver cells, leading to swelling and scarring of the liver. The condition varies from mild or severe. In severe alcoholic hepatitis cases, an individual may need a liver transplant if they do not obtain treatment or do not cease drinking alcohol in the premature phases.
The optimal therapy of alcoholic hepatitis concentrates on decreasing inflammation via the usage of glucocorticoids such as prednisolone, perhaps in combination with N-acetyl cysteine or additional drugs that subdue the immune system. Currently, only short-term gains in survival can be anticipated no therapy has been encountered to improve patient survival past 3 months. Alcohol abstinence is crucial for long-term survival.
The growing prevalence of alcohol-related liver diseases is expected to boost the global market growth during the forecast period. For instance, according to the BioMed Central Ltd Journal 2023, published metal analysis article conclusion the preponderance of alcohol-related liver disease worldwide in 2022 was 4.8%. The preponderance in men was 2.9%, which was more elevated than female (0.5%). Similarly, according to the NIH, in the United States, alcohol is the top reason for liver disease. It affects over 61% of the American population, and out of the 61%, about 10% to 12% are heavy drinkers. Moreover, around 88,000 individuals are affected with alcohol-related diseases yearly, making alcohol the fourth top preventable reason for death in the U.S.
Furthermore, the growing awareness about alcohol related diseases, market developments, increase in research investments and activities are also driving the global market growth during the forecast period.
The stringent regulatory authorities authorizing the drug treatments are expected to hamper the global market growth. Furthermore, high drug development costs and treatment side effects are also expected to hamper the global market growth in the forecast period.
The global alcoholic hepatitis treatment market is segmented based on drug type, route of administration, distribution channel and region.
Owing to the increase in monoclonal antibody drug-type treatment clinical investigations in liver diseases the segment is estimated to hold a large share of the global market. For instance, in February 2023, Imperial College London reported the beginning of a study of phase 2 clinical investigation for Canakinumab 150mg/ml solution for injection. The immediate purpose of the ISAIAH investigation is to examine the probable benefits of utilizing the IL-1B antibody, Canakinumab (injection solution), for treating alcoholic hepatitis.
Moreover, recent conclusions from the pivotal phase 3 IMbrave050 trial examining atezolizumab (Tecentriq, Genentech) plus bevacizumab (Avastin, Genentech) in patients with early-stage hepatocellular carcinoma (HCC) at elevated threat of disease recurrence has encountered that the investigation fulfilled its immediate endpoint of recurrence-free survival (RFS). Also, 9 out of 10 patients of HCC are induced by chronic liver condition, such as includes alcohol-related liver disease, chronic hepatitis B and C infection, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and cirrhosis resulting from these disorders.
The increasing approvals and growing research activities of North America based key players are expected to boost the regional market growth dominating the global market. For instance, in August, 2023, Ocean's small molecule nominee particularly prevents fibrosis advancement in idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak Syndrome (HPS) in multiple testing standards, it was also granted patent for usage in IPF, HPS, alcoholic liver condition, nonalcoholic steatohepatitis (NASH), and scleroderma.
Moreover, in November, 2022, Intercept Pharmaceuticals, Inc. is an American biopharmaceutical corporation reported its strategies concentrated in designing its next-generation FXR agonist, INT-787, in severe alcohol-associated hepatitis (sAH). Alcohol-related liver disease is presently the top indication for liver transplant listing in the U.S., with a significant growth in patients with sAH requiring liver transplantation. Presently, there are no drugs with an authorized indication for the treatment of sAH.
Bunches of analysis have connected the pandemic to an upsurge in heavy drinking and a growth in alcohol-related liver disease (ARLD), with a disproportionate effect on females. Total casualties concerning alcohol grew 25% in 2020, with a 22% growth in alcohol-associated liver disorder casualties.
Moreover, according to the UK government rates of visits to hospitals for the alcoholic liver condition in the financial year ending 2021 stood at the highest at 45.5 per 100,000 population, a total of 24,544 admissions they have been since the financial year completing 2011, and are extremely more elevated compared to in the financial year ending 2020. In a recent analysis publicized in Liver International, investigators at Henry Ford Health System have uncovered that individuals hospitalized for alcoholic hepatitis rose a staggering 50% in the early months of the COVID-19 pandemic. Thus, the rise in the number of patients with alcohol-related liver diseases including hepatitis has led to an increase in the demand for the treatment positively impacting the global market.
The major global players in the market include: Sanofi, Lupin Limited, Genentech, Inc., Teva Pharmaceutical Industries Limited, Pfizer Inc., Alkermes Public Limited Company, Torrent Pharmaceuticals Limited, Wellona Pharma, And Viatris Inc. among others.
The global alcoholic hepatitis treatment market report would provide approximately 61 tables, 59 figures and 186 pages.
LIST NOT EXHAUSTIVE